Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 344

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ISMOH17_013

تاریخ نمایه سازی: 10 اردیبهشت 1398

چکیده مقاله:

Background: Radioligand therapy is the systemic administration of radiopharmaceuticalcomposed of β-emitting radionuclides such as Lutetium chelated to peptide such as PSMA todeliver radiation to prostate cancer cells. This is the first clinical experience with 177Lu-PSMAtherapy in mCRPC patients in IRAN.Methods: total of 17 consecutive patients who were resistant to routine treatment for mCRPCwith median age of 74y (range 55-86) and median PSA level of 870ng/cc (range 5.4-9773) werechosen to enter this study. Bone, lymph nodes and visceral metastases were present in %94(16),%47(8) and %29.5(5) of patients.Results: 12 patients (%70.5) showed decreased level of PSA, out of which (%29.5) had adecline of more than %50. patients showed increased PSA after the first cycle of treatment. Noliver or renal toxicity was noted but hematotoxicity occurred in patients (G1/G2 in (%18) andG3 in one (%6)).Conclusion: Radioligand therapy with 177Lu-PSMA is safe and effective in mCRPC patients

نویسندگان

K. Aryana

Assistant Professor of Nuclear MedicineNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran